National drug policies to local formulary decisions in Thailand, China, and Australia: drug listing changes and opportunities

Yoongthong, Worasuda, Hu, Shanlian, Whitty, Jennifer A., Wibulpolprasert, Suwit, Sukantho, Kitti, Thienthawee, Wannisa, Han, Huixue and Scuffham, Paul A. (2012) National drug policies to local formulary decisions in Thailand, China, and Australia: drug listing changes and opportunities. Value in Health, 15 1 Supp. 1: S126-S131. doi:10.1016/j.jval.2011.11.003


Author Yoongthong, Worasuda
Hu, Shanlian
Whitty, Jennifer A.
Wibulpolprasert, Suwit
Sukantho, Kitti
Thienthawee, Wannisa
Han, Huixue
Scuffham, Paul A.
Title National drug policies to local formulary decisions in Thailand, China, and Australia: drug listing changes and opportunities
Journal name Value in Health   Check publisher's open access policy
ISSN 1098-3015
1524-4733
Publication date 2012-01-01
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1016/j.jval.2011.11.003
Open Access Status DOI
Volume 15
Issue 1 Supp. 1
Start page S126
End page S131
Total pages 6
Place of publication Bangkok, Thailand
Publisher Elsevier
Language eng
Formatted abstract
This commentary is aimed at summarizing the second plenary session presented at the ISPOR 4th Asia-Pacific Conference held in 2010 and compare the issues on drug listing of Thailand, China, and Australia. These countries have substantially different demographic and economic characteristics and health-care financing structures and are in different phases of development of health technology assessment.

In 2008, government expenditure on health per capita in Australia was approximately 60 times that of China and 20 times that of Thailand. The percentage of gross domestic product spent on health care in Australia is twice that of China and Thailand, and the percentage of government-funded health care of total health care is considerably low for China. The proportion of private expenditure on pharmaceuticals in both China and Australia is similar and reflects those of established market economies; in Asia, almost half of all pharmaceutical expenditure is privately funded. Each of the three countries has its own unique challenges and opportunities. These issues are presented for each country following an overview of the policy and drug listing of the three countries.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ
Additional Notes 3rd Special Issue: "Pharmacoeconomics and Outcomes Research in Asia". Proceedings of ISPOR 4th Asia-Pacific Conference, Bangkok, Thailand, 5-7 September 2010.

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collection: School of Pharmacy Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 7 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 11 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 12 Mar 2014, 19:09:11 EST by System User on behalf of School of Pharmacy